Drug class
ATP-competitive pan-AKT kinase inhibitor; targeted antineoplastic
Mechanism of action
Inhibits all three AKT isoforms (AKT1, AKT2 and AKT3), reducing signalling through the PI3K/AKT pathway and downstream pathways involved in tumour-cell growth and survival.
General use cases
- In combination with fulvestrant for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations detected by an FDA-authorised test after progression on or recurrence following endocrine-based therapy
- In combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer under the US FDA indication approved June 12 2026
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
